Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H16ClNO4 |
Molecular Weight | 357.788 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C2N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C(CC(O)=O)C2=C1
InChI
InChIKey=CGIGDMFJXJATDK-UHFFFAOYSA-N
InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)
Molecular Formula | C19H16ClNO4 |
Molecular Weight | 357.788 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02183168 | https://clinicaltrials.gov/ct2/show/NCT02770950 | https://www.ncbi.nlm.nih.gov/pubmed/20503989 | https://www.ncbi.nlm.nih.gov/pubmed/14056924 | https://www.ncbi.nlm.nih.gov/pubmed/27988363
Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02183168 | https://clinicaltrials.gov/ct2/show/NCT02770950 | https://www.ncbi.nlm.nih.gov/pubmed/20503989 | https://www.ncbi.nlm.nih.gov/pubmed/14056924 | https://www.ncbi.nlm.nih.gov/pubmed/27988363
Indometacin (INN and BAN) or indomethacin (AAN, USAN, and former BAN) is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. Indomethacin has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of Indometacin, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Indomethacin is a potent inhibitor of prostaglandin synthesis in vitro. Indomethacin concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because indomethacin is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues. Indometacin is indicated for: Moderate to severe rheumatoid arthritis including acute flares of chronic disease, Moderate to severe ankylosing spondylitis, Moderate to severe osteoarthritis, Acute painful shoulder (bursitis and/or tendinitis), Acute gouty arthritis. In general, adverse effects seen with indomethacin are similar to all other NSAIDs. For instance, indometacin inhibits both cyclooxygenase-1 and cyclooxygenase-2, it inhibits the production of prostaglandins in the stomach and intestines, which maintain the mucous lining of the gastrointestinal tract. Indometacin, therefore, like other non-selective COX inhibitors can cause peptic ulcers. These ulcers can result in serious bleeding and/or perforation requiring hospitalization of the patient. To reduce the possibility of peptic ulcers, indomethacin should be prescribed at the lowest dosage needed to achieve a therapeutic effect, usually between 50–200 mg/day. It should always be taken with food. Nearly all patients benefit from an ulcer protective drug (e.g. highly dosed antacids, ranitidine 150 mg at bedtime, or omeprazole 20 mg at bedtime). Other common gastrointestinal complaints, including dyspepsia, heartburn and mild diarrhea are less serious and rarely require discontinuation of indomethacin.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11906281 |
3.0 nM [IC50] | ||
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20503989 |
10.0 nM [IC50] | ||
Target ID: CHEMBL4681 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23432095 |
100.0 nM [IC50] | ||
Target ID: CHEMBL1835 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2547071 |
100.0 nM [IC50] | ||
Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12142058 |
|||
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12142058 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | INDOCIN Approved UseTIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1). Launch Date-1.43942402E11 |
|||
Primary | INDOCIN Approved UseTIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1). Launch Date-1.43942402E11 |
|||
Primary | INDOCIN Approved UseTIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1). Launch Date-1.43942402E11 |
|||
Primary | INDOCIN Approved UseTIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1). Launch Date-1.43942402E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2369 ng/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2 μg/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7762 ng × h/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.22 h |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.9 g single, oral Overdose Dose: 0.9 g Route: oral Route: single Dose: 0.9 g Sources: Page: p.152 |
unhealthy, 15 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.152 |
Disc. AE: Vomiting, Nausea... AEs leading to discontinuation/dose reduction: Vomiting Sources: Page: p.152Nausea (mild) Anorexia (mild) |
20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Other AEs: Headache, Pruritus... Other AEs: Headache (below serious, 11 patient) Sources: Pruritus (below serious, 5 patients) |
20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 92 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 92 Sources: |
Other AEs: Nausea, Vomiting... Other AEs: Nausea (below serious, 34 patients) Sources: Vomiting (below serious, 11 patient) Constipation (below serious, 8 patients) |
40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Other AEs: Deep vein thrombosis, Headache... Other AEs: Deep vein thrombosis (serious, 1 patient) Sources: Headache (below serious, 13 patients) Pruritus (below serious, 1 patient) Presyncope (below serious, 5 patients) |
40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Other AEs: Nausea, Vomiting... Other AEs: Nausea (below serious, 36 patients) Sources: Vomiting (below serious, 12 patients) Constipation (below serious, 7 patients) Post procedural haemorrhage (below serious, 7 patients) |
40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Other AEs: Headache, Pruritus... Other AEs: Headache (below serious, 12 patients) Sources: Pruritus (below serious, 3 patients) |
40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 94 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 94 Sources: |
Other AEs: Headache, Vomiting... Other AEs: Headache (below serious, 17 patients) Sources: Vomiting (below serious, 9 patients) |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Disc. AE: Cardiac thrombosis, Myocardial infarction... AEs leading to discontinuation/dose reduction: Cardiac thrombosis (serious) Sources: Myocardial infarction (grade 3-5) Stroke (grade 3-5) Gastrointestinal disorder NOS (serious) Bleeding (grade 3-5) Ulceration (grade 3-5) Perforation stomach (grade 3-5) Perforation of intestine (grade 3-5) |
0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Other AEs: Gingival bleeding, Application site pruritus... Other AEs: Gingival bleeding (below serious, 1 patient) Sources: Application site pruritus (below serious, 1 patient) Inflammation (below serious, 1 patient) Nasopharyngitis (below serious, 1 patient) Ligament sprain (below serious, 1 patient) Rash (below serious, 2 patients) Drug eruption (below serious, 1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Vomiting | Disc. AE | 0.9 g single, oral Overdose Dose: 0.9 g Route: oral Route: single Dose: 0.9 g Sources: Page: p.152 |
unhealthy, 15 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.152 |
Anorexia | mild Disc. AE |
0.9 g single, oral Overdose Dose: 0.9 g Route: oral Route: single Dose: 0.9 g Sources: Page: p.152 |
unhealthy, 15 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.152 |
Nausea | mild Disc. AE |
0.9 g single, oral Overdose Dose: 0.9 g Route: oral Route: single Dose: 0.9 g Sources: Page: p.152 |
unhealthy, 15 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.152 |
Headache | below serious, 11 patient | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Pruritus | below serious, 5 patients | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Vomiting | below serious, 11 patient | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 92 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 92 Sources: |
Nausea | below serious, 34 patients | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 92 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 92 Sources: |
Constipation | below serious, 8 patients | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 92 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 92 Sources: |
Pruritus | below serious, 1 patient | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Headache | below serious, 13 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Presyncope | below serious, 5 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Deep vein thrombosis | serious, 1 patient | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Vomiting | below serious, 12 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Nausea | below serious, 36 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Constipation | below serious, 7 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Post procedural haemorrhage | below serious, 7 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Headache | below serious, 12 patients | 40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Pruritus | below serious, 3 patients | 40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Headache | below serious, 17 patients | 40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 94 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 94 Sources: |
Vomiting | below serious, 9 patients | 40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 94 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 94 Sources: |
Bleeding | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Myocardial infarction | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Perforation of intestine | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Perforation stomach | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Stroke | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Ulceration | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Cardiac thrombosis | serious Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Gastrointestinal disorder NOS | serious Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Application site pruritus | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Drug eruption | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Gingival bleeding | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Inflammation | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Ligament sprain | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Nasopharyngitis | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Rash | below serious, 2 patients | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Letter: Aspirin sensitivity: other drugs. | 1975 Feb |
|
[Clinical results of a multicentral double-blind examination of naproxen compared to indomethacin in chronic rheumatoid arthritis, ankylosing spondylitis, and osteoarthrosis]. | 1975 Feb |
|
Decrease in nucleophosmin/B23 mRNA and telomerase activity during indomethacin-induced apoptosis of gastric KATO-III cancer cells. | 1999 Dec |
|
Activation of apoptotic caspase-3 and nitric oxide synthase-2 in gastric mucosal injury induced by indomethacin. | 1999 Feb |
|
Regression of ductus arteriosus aneurysm in a neonate demonstrated by three-dimensional computed tomography. | 1999 Feb 28 |
|
[Psychiatric side effects of non-steroidal anti-inflammatory agents]. | 1999 Jan-Feb |
|
Spinal antinociceptive effect of epidural nonsteroidal antiinflammatory drugs on nitric oxide-induced hyperalgesia in rats. | 1999 Jul |
|
Induction of stromelysin gene expression by tumor necrosis factor alpha is inhibited by dexamethasone, salicylate, and N-acetylcysteine in synovial fibroblasts. | 1999 Jun |
|
Nitric oxide, superoxide radicals and mast cells in pathogenesis of indomethacin-induced small intestinal lesions in rats. | 1999 Mar |
|
Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase. | 1999 May |
|
Enhancement of low density lipoprotein catabolism by non-steroidal anti-inflammatory drugs in cultured HepG2 cells. | 1999 May 21 |
|
Indomethacin reduces the skin thermal damage in hyperthermic treatment of experimental malignant tumors. | 1999 May-Jun |
|
Capsaicin-sensitive afferent sensory nerves in modulating gastric mucosal defense against noxious agents. | 1999 Nov |
|
Effect of anti-CD11b (alphaM-MAC-1) and anti-CD54 (ICAM-1) monoclonal antibodies on indomethacin induced chronic ileitis in rats. | 1999 Nov |
|
Tubulointerstitial nephritis with anti-neutrophil cytoplasmic antibody following indomethacin treatment. | 1999 Nov |
|
Indomethacin treatment decreases renal blood flow velocity in human neonates. | 1999 Nov |
|
Can dopamine prevent the renal side effects of indomethacin? A prospective randomized clinical study. | 1999 Nov-Dec |
|
Indomethacin induced gastropathy in CD18, intercellular adhesion molecule 1, or P-selectin deficient mice. | 1999 Oct |
|
Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. | 1999 Oct 2 |
|
Dual action of nitric oxide in pathogenesis of indomethacin-induced small intestinal ulceration in rats. | 1999 Sep |
|
Indomethacin-induced postoperative psychosis. | 1999 Sep |
|
Neuropeptide Y enhances potassium excretion by mechanisms distinct from those controlling sodium excretion. | 2000 Feb |
|
Bartter syndrome in a neonate: early treatment with indomethacin. | 2000 Feb |
|
Induction of antitumor immunity by indomethacin. | 2000 Feb |
|
Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. | 2000 Jan |
|
Inhibition of carrageenan-induced edema by indomethacin or sodium salicylate does not prevent the increase of nerve growth factor in the rat hind paw. | 2000 Jan 14 |
|
Indomethacin decreases insulin secretion in patients with type 2 diabetes mellitus. | 2000 Jul |
|
The influence of indomethacin on the acth secretion induced by central stimulation of adrenergic receptors. | 2000 Jun |
|
Regrowth of 5-fluorouracil-treated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin, and phenylbutyrate. | 2000 Jun 15 |
|
Effect of indomethacin on IL-1beta, IL-6 and TNFalpha production by mononuclear cells of preterm newborns and adults. | 2000 Mar |
|
Role of endothelin-converting enzyme-1 in the suppression of constitutive nitric oxide synthase in rat gastric mucosal injury by indomethacin. | 2000 Nov |
|
Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin. | 2000 Nov |
|
Keratinocyte growth factor-2 (FGF-10) promotes healing of experimental small intestinal ulceration in rats. | 2000 Nov |
|
Inhibition of inducible nitric oxide synthase gene expression by indomethacin or ibuprofen in beta-amyloid protein-stimulated J774 cells. | 2000 Nov 17 |
|
A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. | 2000 Sep 7 |
|
Stimulation of cyclooxygenase-2-activity by nitric oxide-derived species in rat chondrocyte: lack of contribution to loss of cartilage anabolism. | 2001 Apr 15 |
|
Indomethacin increases 15-PGDH mRNA expression in HL60 cells differentiated by PMA. | 2001 Feb |
|
Does exposure to magnesium sulfate in utero decrease the risk of necrotizing enterocolitis in premature infants? | 2001 Feb |
|
Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. | 2001 Feb |
|
Lack of small intestinal ulcerogenecity of nitric oxide-releasing indomethacin, NCX-530, in rats. | 2001 Feb |
|
Increased 15-HPETE production decreases prostacyclin synthase activity during oxidant stress in aortic endothelial cells. | 2001 Feb 1 |
|
An investigation into the thermal behaviour of an amorphous drug using low frequency dielectric spectroscopy and modulated temperature differential scanning calorimetry. | 2001 Jan |
|
Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. | 2001 Jan |
|
Protective role of cyclooxygenase inhibitors in the adverse action of passive cigarette smoking on the initiation of experimental colitis in rats. | 2001 Jan 5 |
|
Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo. | 2001 Mar 1 |
|
Indomethacin prevents the induction of inducible nitric oxide synthase in murine peritoneal macrophages and decreases their nitric oxide production. | 2001 Mar 9 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27988363
U251 cells were incubated for 24 h with different concentrations of indomethacin (0.03, 0.06, 0.13, 0.25, 0.5, 1 mkM), diclofenac (DIC),naproxen (NAP), or ketoprofen (KET), and the cell viability was assessed by MTT or crystal violet (CV) tests.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 16:15:41 UTC 2022
by
admin
on
Fri Dec 16 16:15:41 UTC 2022
|
Record UNII |
XXE1CET956
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000000160
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
||
|
NCI_THESAURUS |
C1323
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
||
|
WHO-VATC |
QS01BC01
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
||
|
WHO-VATC |
QC01EB03
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
||
|
NCI_THESAURUS |
C54677
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
||
|
NDF-RT |
N0000175721
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
||
|
LIVERTOX |
NBK548001
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
||
|
WHO-ATC |
M02AA23
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
||
|
NDF-RT |
N0000175722
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
||
|
WHO-VATC |
QM01AB01
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
||
|
WHO-ATC |
M01AB01
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
||
|
WHO-ATC |
S01BC01
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
||
|
WHO-VATC |
QM02AA23
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
||
|
WHO-ATC |
S01CC02
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
||
|
WHO-VATC |
QM01AB51
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
||
|
WHO-ATC |
M01AB51
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
||
|
WHO-ATC |
C01EB03
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL6
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | |||
|
DB00328
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | |||
|
M6279
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | Merck Index | ||
|
5781
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | RxNorm | ||
|
D007213
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | |||
|
Indomethacin
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | |||
|
XXE1CET956
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | |||
|
DTXSID9020740
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | |||
|
SUB08180MIG
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | |||
|
49662
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | |||
|
757061
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | |||
|
XXE1CET956
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | |||
|
1524
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | |||
|
77541
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | |||
|
1341001
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | |||
|
3101
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | |||
|
3715
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | |||
|
INDOMETHACIN
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | Description: A white or a pale yellow, crystalline powder; odourless or almost odourless. Solubility: Practically insoluble in water; sparingly soluble in ethanol (~750 g/l) TS and ether R. Category: Analgesic; anti-inflammatory. Storage: Indometacin should be kept in a well-closed container, protected from light. Additional information: Indometacin exhibits polymorphism. The polymorph specified in the monograph corresponds to the crystal form of indometacin RS.Definition: Indometacin contains not less than 98.0% and not more than 101.0% of C19H16ClNO4, calculated with reference to the dried substance. | ||
|
1440
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | |||
|
C576
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | |||
|
53-86-1
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | |||
|
1909
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | |||
|
200-186-5
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY | |||
|
INDOMETACIN
Created by
admin on Fri Dec 16 16:15:41 UTC 2022 , Edited by admin on Fri Dec 16 16:15:41 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
TRANSPORTER -> INHIBITOR |
|
||
|
DEGRADENT -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |